menu
    • menu
    [{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SRA737","moa":"Chk1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Momelotinib","moa":"JAK1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Momelotinib","moa":"JAK1","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sierra Oncology","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Sierra Oncology"},{"orgOrder":0,"company":"GSK","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"GSK \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Jefferies"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Momelotinib

    Menu

    Momelotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GSK’s Omjjara receives Japanese approval for treatment of myelofibrosis

                            Details : Omjjara (momelotinib) is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. It is indicated for the treatment of myelofibrosis.

                            Brand Name : Omjjara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 25, 2024

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Commission Authorises GSK’s Omjjara (momelotinib)

                            Details : Omjjara (momelotinib) is an oral JAK1/JAK2 and ACVR1 inhibitor for treating splenomegaly and symptoms in adult myelofibrosis patients with moderate to severe anemia.

                            Brand Name : Omjjara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 29, 2024

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GSK rEceives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

                            Details : GS-0387 (momelotinib) has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1). It is being evaluated for the treatment of myelofibrosis pati...

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2023

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ojjaara (Momelotinib) Approved in the US as the First And Only Treatment Indicated for Myelofibrosis Patients ...

                            Details : Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.

                            Brand Name : Ojjaara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2023

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gsk Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese R...

                            Details : GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2023

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GSK Announces Extension Of Fda Review Period For Momelotinib

                            Details : GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 16, 2023

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Medicines Agency Accepts Marketing Authorisation Application for Momelotinib for The Treatment of Mye...

                            Details : GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1 and JAK2 and activin A receptor type I (ACVR1).

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Accepts New Drug Application for GSK’s Momelotinib for the Treatment of Myelofibrosis

                            Details : GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, and JAK2 and activin A receptor, type I (ACVR1).

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 17, 2022

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            GSK Completes Acquisition of Sierra Oncology

                            Details : Momelotinib (GS-0387), has a differentiated mode of action with inhibitory ability along three key signalling pathways: activin A receptor, type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase (JAK) 1, and JAK2.

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : $1,900.0 million

                            July 01, 2022

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

                            Details : GS-0387 (momelotinib) is a potent, selective and orally bioavailable ACVR1 / ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.

                            Brand Name : GS-0387

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 17, 2022

                            Lead Product(s) : Momelotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth